Adage Capital Partners Gp, L.L.C. Hille Vax, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$14.15 - $19.75 $1.76 Million - $2.45 Million	-124,219 Reduced 62.6%	74,220 $1.23 Million
Q4 2023 Feb 14, 2024	BUY	$10.35 - $17.11 $226,944 - $375,170	21,927 Added 12.42%	198,439 $3.18 Million
Q3 2023 Nov 14, 2023	BUY	$11.59 - $16.7 $2.05 Million - $2.95 Million	176,512 New	176,512 $2.37 Million

36.8M

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $66.9M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.